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Abstract
Introduction: Cryptococcal meningitis is the most common neurological infection in HIV infected patients in Sub Saharan
Africa, where gold standard treatment with intravenous amphotericin B and 5 flucytosine is often unavailable or difficult to
administer. Fluconazole monotherapy is frequently recommended in national guidelines but is a fungistatic drug
compromised by uncertainty over optimal dosing and a paucity of clinical end-point outcome data.
Methods: From July 2010 until March 2011, HIV infected adults with a first episode of cryptococcal meningitis were
recruited at Queen Elizabeth Central Hospital, Blantyre, Malawi. Patients were treated with oral fluconazole monotherapy
800 mg daily, as per national guidelines. ART was started at 4 weeks. Outcomes and factors associated with treatment
failure were assessed 4, 10 and 52 weeks after fluconazole initiation.
Results: Sixty patients were recruited. 26/60 (43%) died by 4 weeks. 35/60 (58.0%) and 43/56 (77%) died or failed treatment
by 10 or 52 weeks respectively. Reduced consciousness (Glasgow Coma Score ,14 of 15), moderate/severe neurological
disability (modified Rankin Score .3 of 5) and confusion (Abbreviated Mental Test Score ,8 of 10) were all common at
baseline and associated with death or treatment failure. ART prior to recruitment was not associated with better outcomes.
Conclusions: Mortality and treatment failure from cryptococcal meningitis following initiation of treatment with 800 mg
oral fluconazole is unacceptably high. To improve outcomes, there is an urgent need for better therapeutic strategies and
point-of-care diagnostics, allowing earlier diagnosis before development of neurological deficit.
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Introduction
Cryptococcal meningitis, caused by the encapsulated sapro-
phytic yeast Cryptococcus neoformans, occurs most commonly in HIV
infected patients with CD4 counts of 100 cells/ml or less [1,2]. As a
consequence of the HIV epidemic, it is the most common cause of
meningitis amongst adults in Sub Saharan Africa (SSA) [3–5]. Of
an estimated global incidence of 957,900 cases per year, 75%
occur in SSA [6].
Unacceptable differences in mortality exist between developed
and developing countries. Ten week case fatality rates have been
estimated at 9% in Western Europe and North America, but as
high as 70% in SSA [6]. There is no evidence that mortality in
SSA has improved since the roll-out of antiretroviral therapy
(ART) and uncertainty over optimal treatment regimens for
resource limited settings is partially responsible for this. ’’Gold-
standard’’ therapy involves a two week induction phase with the
fungicidal combination amphotericin B and flucytosine prior to
consolidation and maintenance therapy with fluconazole [7].
However, the cost, complexities of administration and side effects
prevent the routine use of this regimen in resource poor settings.
Standard treatment in Africa usually consists of fluconazole
monotherapy.
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Fluconazole is a fungistatic drug and past studies have shown
poor clinical outcomes from monotherapy; in Uganda and Zambia
administration of 200 mg/day resulted in 1–2 month survival of
only 10–12% [8,9]and in South Africa doubling the dose to
400 mg did not improve in-hospital survival [10]. A recent study
demonstrated that dose escalation to 1200 mg/day achieves faster
fungal clearance from cerebrospinal fluid (CSF) without increased
toxicity [11,12], but clinical end-point studies are lacking. At the
time of the study, Malawian national guidelines stipulated the use
of oral fluconazole at a dose of 800 mg [13].
Increasingly, early ART introduction has been advocated in
patients suffering from opportunistic infections. Therefore, several
African countries including Malawi now recommend commencing
ART within a month of diagnosis of cryptococcal meningitis
[13,14]. However, patients who initiate ART very early (i.e. 3 days
after starting 800 mg oral fluconazole) are at risk of intracranial
Immune Reconstitution Inflammatory Syndrome (IRIS), which is
often severe and can be fatal [15]. It is possible that patients
initiated on fungistatic therapy are at greater risk of IRIS as the
pathogen persists for longer. Conclusive data are lacking on the
optimal time for initiating ART in these patients.
Within the last 5 years evidence has emerged that regimens
incorporating short courses of amphotericin B may be safely and
effectively used in South Africa and Uganda [16–20]. Clinical
trials are now proposed using different combinations of ampho-
tericin B, flucytosine and fluconazole to establish the best
approach to treatment in resource poor settings. While prepara-
tions for these trials are underway, accurate clinical outcome data
from a fluconazole-monotherapy regimen are required to provide
a meaningful comparison from a high incidence and resource-poor
setting.
From July 2010 until March 2011, 60 consecutive patients with
confirmed cryptococcal meningitis in Blantyre, Malawi, were
recruited and treated according to national guidelines [13]. They
were followed-up for one year in order to determine clinical
outcomes from cryptococcal meningitis in a resource limited
setting following treatment induction with 800 mg oral fluconazole
as monotherapy.
Methods
Ethics Statement
The study was prospectively approved by the University of
Malawi, College of Medicine Research Ethics Committee
(COMREC protocol P.04/10/926). Cryptococcal meningitis
may impair a patient’s cognitive function to the extent that
assistance of a guardian was required for discussions with the study
team and therefore verbal consent was requested to approach all
patients on diagnosis of the condition. Informed written consent to
enter the study was obtained from patients or their guardians if
unconscious. The study itself was completely observational: all
procedures performed and medications commenced by the
Figure 1. A shows survival on fluconazole therapy for all 60 patients. The solid line shows estimated proportion of survivors and the dotted
lines show 95% confidence intervals. Amongst the 47 patients who did not survive on fluconazole to 52 weeks, two had positive CSF cultures at 10
weeks and were switched to fluconazole. The remaining 45 died. B shows survival on fluconazole stratified by baseline GCS. 2 patients (one who died
in the first week and one who survived to 52 weeks) were excluded from this analysis as no baseline GCS was recorded. The solid line represents
patients with baseline GCS$14 and the dotted line represents patients with baseline GCS,14. Hazard ratio for death or treatment failure by 52
weeks: 2.09, 95% CI: 1.07–4.06 p = 0.030.
doi:10.1371/journal.pone.0067311.g001
Cryptococcal Meningitis Fatality:800mg Fluconazole
PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e67311
authors were consistent with their roles as attending physicians
within the hospital. National and local guidelines and protocols for
the management of cryptococcal meningitis and HIV were strictly
adhered to by the study team in the routine care of the patients.
Setting
Queen Elizabeth Central Hospital (QECH) is a 1,500 bed
hospital in Blantyre, Malawi. It serves a population of approxi-
mately 1 million in the Blantyre District and takes tertiary referrals
from further afield. Inpatient prevalence of HIV has been
estimated at 70% amongst adult patients [21]. Since 2000, the
Malawi Liverpool Wellcome Trust Clinical Research Programme
(MLW) has offered a routine, quality controlled, diagnostic
microbiology service for samples of cerebrospinal fluid (CSF)
taken from adults and children presenting with clinical features
suggestive of meningitis.
Recruitment and Clinical Assessment
Patients were eligible for recruitment if they received a first
microbiological diagnosis of cryptococcal meningitis following
either positive India-Ink microscopy or positive culture of CSF.
Malawian national guidelines for the treatment of Cryptococcal
meningitis were followed; treatment was initiated with oral
fluconazole 800 mg once daily (od) for 2 weeks, followed by
400 mg od for 6 weeks, then secondary prophylaxis with 200 mg
od indefinitely [13].
Baseline demographic and clinical data were recorded including
presence of fever (body temperature .37.5uC) and cranial nerve
palsies or focal neurological signs. Prior use of ART and CD4
count at baseline were noted. Three aspects of overall neurological
function were assessed; consciousness by Glasgow Coma Score
(GCS), physical disability by modified Rankin Score (mRS) and
cognition by Abbreviated Mental Test Score (AMTS). mRS is a 6
point scale (0 =No symptoms, 1=No significant disability,
2 =Minor disability,3 =Moderate disability, 4 =Moderate-severe
disability, 5 = Severe disability/bed-ridden), which has previously
been used in Malawi for stroke patients [22]. AMTS is the sum of
correct responses to 10 standard questions [23], adapted for
Malawi by changing ‘‘When did World War I begin?’’ to ‘‘When
did Malawi attain independence?’’ and replacing ‘‘Name the
current UK monarch’’ with ‘‘Name the current Malawian
president’’. AMTS has not been validated in Malawi and results
may be subject to bias by cultural background and educational
attainment [24], however there was no better method of assessing
cognition available.
It was not possible to measure CSF pressure and LPs were only
repeated if patients developed clinical features of raised intra-
cranial pressure.
Patients were reviewed 4, 10 and 52 weeks after initiation of
fluconazole, and encouraged to contact the study team at any time
if clinical deterioration occurred. ART was commenced 4 weeks
into fluconazole therapy. The study team ensured continuous
access to fluconazole and ART.
Table 1. Baseline factors associated with treatment outcome by 4 weeks.
Variable Total n =60
Failed Treatment
1 n=26 Survived n=34 Hazard ratio (for death)
Hazard ratio 95% CI p-value
Demographics and clinical presentation
Age, years (median, IQR) 32 (29–39) 35 (28–40) 31 (29–37) 1.03 0.98–1.07 0.286
Male sex (n, %) 33 (55) 14 (54) 19 (56) 0.91 0.42–1.96 0.802
Headache duration, days (median, IQR) 14 (5–30) 14 (4–30) 17.5 (7–30) 1.00 0.99–1.02 0.707
Fever - temperature .37.5uC (n, %) 21 (37) 12 (52) 9 (27) 2.27 1.00–5.15 0.050
Cranial nerve palsy or localising neurological
signs (n, %)
5 (10) 2 (8) 3 (9) 1.06 0.25–4.48 0.938
Overall neurological function
Baseline GCS ,14 (n, %)2 14 (24) 9 (36) 5 (15) 2.27 0.99–5.11 0.051
Modified Rankin Score (mRS) .3/5 (n, %) 24 (40) 16 (62) 8 (24) 3.00 1.36–6.63 0.007
Abbreviated Mental Test Score (AMTS) ,8/10
(n,%)3
13 (30) 8 (57) 5 (17) 3.97 1.37–11.50 0.010
HIV Parameters
On ART at baseline (n, %)4 13 (36) 6 (38) 7 (35) 1.21 0.44–3.34 0.709
CSF parameters
$5 White cells/mm3in CSF (n, %) 44(76) 20 (77) 25 (76) 1.18 0.46–0.72 0.724
White cell count in CSF (median cells/mm3, IQR)20 (5–74) 18 (10–73) 29 (4–72) 1.00 1.00–1.00 0.787
CSF glucose below ,2.2 mmol/l (n, %)5 27 (61.4) 14 (78) 13 (50) 3.13 1.03–9.53 0.045
CSF protein .0.4 g/L (n, %)6 39 (84.8) 16 (80) 23 (89) 0.71 0.24–2.14 0.546
CSF India Ink stain positive (n, %) 36 (61) 16 (61) 20 (61) 1.02 0.46–2.24 0.966
1All treatment failures in the first 4 weeks died.
2Baseline GCS known for 58 patients (25 failed, 33 survived).
3Baseline AMTS performed on 44 patients (14 failed, 30 survived).
4ART status known for 36 patients (n = 16 failed, n = 20 survived).
5CSF glucose result available from 44 patients (18 failed, 26 survived).
6CSF protein results available from 46 patients (20 failed, 26 survived).
doi:10.1371/journal.pone.0067311.t001
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Treatment outcomes were defined as survival or treatment
failure (death or therapy changed to amphotericin B following
clinical deterioration with persistently positive CSF cultures after
one month of fluconazole). This pragmatic approach to refractory
cases was necessitated by a limited supply of amphotericin B, a
shortage of trained staff to administer the drug and a lack of
routine diagnostic biochemistry to monitor side effects.
Laboratory Methods
All CSF diagnostic testing was performed at MLW. Cell counts
were performed using a FastRead (Immune Systems) disposable
counting chamber. India-Ink microscopy was performed on all
unclotted samples of adequate volume. All samples were cultured
on sheep blood and chocolate agar for 48 hours under aerobic and
microaerophilic conditions and sub-cultured onto sabouraud agar
and urea slopes if they were India-Ink positive or culture yielded
yeasts. Bacteria and yeasts were identified using standard methods
[25]. Neither cryptococcal antigen testing nor antifungal suscep-
tibility testing was routinely available. Mycobacterial culture of
CSF was not performed. The MLW laboratory participates in
internationally recognised quality control programmes including
NEQAS (UK) and the South African NHLS scheme. Full blood
count and CD4 count were performed at the main QECH
laboratory.
Statistics
Clinical and microbiological data was stored in a Microsoft
Excel file and analysed using ‘‘R’’ version 2.12.1. Baseline
characteristics and treatment outcomes were reported by simple
descriptive statistics. A two-sample Wilcoxon test was used to
assess the relationship between baseline CD4 count and prior
ART. Kaplan-Meier plots were used to demonstrate survival on
fluconazole by 52 weeks. Data from previous studies suggest that
deaths within the first month of treatment are directly attributable
to cryptococcal meningitis whilst later deaths are multi-factorial
[26]. Therefore, analysis of variables associated with poor outcome
was done using Cox proportional hazards regression modelling
with an end-point of ‘‘time to death’’ during the first four weeks.
Hazard Ratios (HRs) with 95% confidence intervals (CI) were
presented. This analysis was repeated using alternative end-points
of ‘‘time to death or treatment failure’’ during 10 and 52 weeks of
follow-up. In all analyses, a p-value of ,0.05 was considered
statistically significant.
Results
Baseline Demographic and Clinical Features
Sixty patients with a first episode of cryptococcal meningitis
were recruited. Thirty-three (55%) were male and the median age
was 32 years (range: 15–62). All patients complained of headache
at presentation, with a median duration of 14 days (range: 1–150).
21 (37%) were febrile.
Baseline GCS was ,14 of 15 in 14/58 (24%) patients. mRS
was .3 (moderate disability) in 24/60 (40%) patients. 13/44
(30%) patients who completed an AMTS on admission obtained a
score of ,8/10. Five (10%) patients had localising neurological
signs (two with focal weakness, two with cranial nerve VI palsies
and one with both of these abnormalities).
All patients were HIV-infected. Thirty-two had a CD4 count
result available, the median result was 37cells/ml (range: 2–234
cells/ml). Thirteen (22%) patients were on ART at presentation.
Their median CD4 count was 55 cells/ml (range: 2–234cells/ml).
There was no association between CD4 count and prior ART
(two-sample Wilcoxon test, p = 0.69).
Table 2. Baseline factors associated with treatment outcome by 10 and 52 weeks.
Variable
Treatment outcomes by 10 weeks
Hazard ratio (for death or failure)
Treatment outcomes by 52 weeks
Hazard ratio (for death or failure)
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
Demographics and clinical presentation
Age, years (median, IQR) 1.01 0.96–1.05 0.758 1.01 0.96–1.05 0.803
Male sex (n, %) 0.69 0.35–1.34 0.273 0.70 0.39–1.29 0.254
Headache duration, days (median, IQR) 1.00 0.99–1.01 0.790 1.00 0.99–1.01 0.528
Fever - temperature .37.5uC (n, %) 1.47 0.72–2.98 0.295 1.27 0.66–2.41 0.469
Cranial nerve palsy or localising neurological signs (n,
%)
0.76 0.18–3.18 0.709 1.78 0.62–4.94 0.285
Overall neurological function
Baseline GCS ,14 2.23 1.08–4.62 0.030 2.09 1.07–4.06 0.030
Modified Rankin Score (mRS) .3/5.3/5 (n, %) 2.28 1.17–4.47 0.011 1.76 0.96–3.22 0.068
Abbreviated Mental Test Score (AMTS) ,8/10 2.96 1.28–6.85 0.011 2.41 1.12–5.19 0.024
HIV Parameters
On ART at baseline (n, %) 1.46 0.62–3.42 0.385 1.47 0.68–3.19 0.326
CSF parameters
.5 White cells/ml in CSF (n, %) 1.05 0.35–0.89- 0.984 0.93 0.49–1.77- 0.831
White cell count in CSF (cells/mm3) 1.00 0.99–1.01 0.841 0.99 0.99–1.00 0.676
CSF glucose below ,2.2 mmol/l (n, %)6 1.81 0.77–4.25 0.172 1.29 0.63–2.62 0.483
CSF protein .0.5 g/L (n, %) 0.66 0.25–1.78 0.414 0.60 0.26–1.40 0.239
CSF India Ink stain positive (n, %) 0.82 0.42–1.60 0.559 0.86 0.47–1.56 0.607
doi:10.1371/journal.pone.0067311.t002
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Baseline CSF Characteristics
All 60 patients had evidence of cryptococcal infection in their
CSF; 57 (95%) were culture positive and the remaining 3 (5%) had
positive microscopy but no culture result available. White cells
were seen in the CSF of 45 (75%) patients. The median white cell
count was 20 cells/ml (range: 0–520).
Forty-six patients had a documented CSF protein result and
46 a documented CSF glucose. Median CSF protein was 0.78 g/L
(range: 0.23–4.04, normal 0.15–0.40 g/L) and median CSF
glucose was 1.97 mmol/L (range: 0.06–3.65, normal 2.22–
3.88 mmol/L). 39/46 (85%) patients had high CSF protein and
27/44 (61%) had low CSF glucose values.
Treatment Outcomes
26/60 (43%) patients died in the first 4 weeks. A total of 33
(55%) died by 10 weeks, and a further 2 failed fluconazole
monotherapy so were switched to intravenous amphotericin B
between weeks 2 and 10. In total, 35/60 (58%) patients had
fluconazole treatment failure by 10 weeks.
Between weeks 10 and 52, a further 8 patients died and 4 were
lost to follow-up. There were only 13 known survivors one year
after presentation. Of these, six were reviewed in person and seven
were interviewed by telephone. The six presenting for review were
taking both ART and secondary fluconazole prophylaxis. All had
good neurological recovery (6 had AMTS=10, 5 had mRS=0,
and one had mRS=1). In total 43/56 (77%) of patients had failure
of treatment of cryptococcal meningitis at one year following
treatment induction with 800 mg oral fluconazole. Figure 1a
shows that the probability of survival on fluconazole monotherapy
for 4 weeks was 55% (95% CI: 44–70%), for 10 weeks was 43%
(95% CI: 32–58%) and for one year was 22% (95% CI: 14–36%).
Baseline Clinical Factors Associated with Treatment
Outcome
Table 1 shows univariate analysis of associations between
baseline variables and time to death during the first 4 weeks. Of
the clinical factors, mRS.3 (HR: 3.00, 95% CI: 1.36–6.63) and
AMTS score ,8/10 (HR: 3.97, 95% CI: 1.37–11.50) were
associated with shorter survival and there were strong trends
towards earlier death with fever (HR: 2.27, 95% CI: 1.00–5.15)
and GCS,14 (HR: 2.27 95%CI: 0.99–5.11). Of the laboratory
factors, CSF glucose ,2.2 mmol/l (HR: 3.13, 95% CI: 1.03–9.53)
was associated with earlier death. Multivariate analysis was
precluded by a high degree of co-linearity between clinical
variables describing overall neurological function (mRS, AMTS
and GCS), and the number of missing data-points amongst some
laboratory variables.
When the univariate analysis was repeated with end-points of
treatment failure by 10 or 52 weeks (Table 2), the importance of
low CSF glucose concentration and fever at baseline were lost.
However, on 10 week analysis AMTS,8/10 (HR: 2.96, 95%CI:
1.28–6.85), mRS.3 (HR: 2.96, 95%CI: 1.17–4.47) and GCS,14
(HR: 2.23, 95% CI: 1.08–4.62) were significantly associated with
shorter survival. On 52 week analysis AMTS,8/10 (HR: 2.41,
95% CI: 1.07–4.06) and GCS,14 (HR: 2.09, 95% CI: 1.07–4.06)
remained significant. Figure 1b demonstrates the probability of
survival on fluconazole over 52 weeks sub-divided by baseline
GCS,14 or .14.
Prior ART was not associated with better outcomes. Of the 13
patients on ART at baseline, 9 (69%) had died at 10 weeks and 11
(84%) at one year. As HIV viral loads, quantitative CSF fungal
culture and CSF mycobacterial culture were unavailable, it was
impossible to distinguish cryptococcal IRIS, HIV treatment failure
and other causes of cerebral infection or IRIS.
CD4 counts were unavailable for 28 patients, 11 of who died
within the first 4 weeks so were not used in the analysis.
Discussion
Clinical outcomes from cryptococcal meningitis in HIV infected
Malawian adults following treatment induction with 800 mg oral
fluconazole were poor, with 43% mortality at 4 weeks, 58%
treatment failure at 10 weeks and 77% treatment failure at 1 year.
These data are consistent with prior studies of fluconazole
monotherapy at both lower [8–10] and identical [11] doses in
Africa and show only a modest improvement from the pre-ART
and pre-fluconazole era. The 58% treatment failure rate at 10
weeks is similar to the 60% (18/30 patients) seen in a smaller
cohort from a fluconazole dose response study in Uganda [11].
Malawi has since increased the induction phase dose of
fluconazole to 1200 mg, although clinical end-point data from
randomised controlled studies using this regimen are unavailable.
The contribution of baseline clinical and laboratory variables to
poor outcomes by 4, 10 and 52 weeks was assessed. Although
AMTS provides an imperfect assessment of cognitive function, a
score of ,8/10 was associated with earlier death or treatment
failure at all time-points. Prior studies have reported similar results
[26], suggesting that altered mental status at presentation is a
persistently strong prognostic marker. Moderate or severe
functional disability (mRS.3) and reduced consciousness
(GCS,14), another marker of altered mental status were also
associated with shorter survival by early and late time-points of
analysis.
Fever (temperature .37.5uC) and low CSF glucose measure-
ments (,2.2 mmol/l) were associated with poor outcomes by 4
weeks but were insignificant by later time-points. This finding is
consistent with data suggesting the longer an individual survives,
the less likely that subsequent death is due to cryptococcal
meningitis [26]. Conversely, patients with impaired cognition,
functional disability or reduced consciousness are at prolonged
higher risk of poor adherence to medications and late treatment
complications such as pressure sores, intercurrent infection and
thrombosis. This may explain why baseline neurological deficit
remained strongly linked to poor outcome after one year of follow-
up.
The high incidence of altered mental status at baseline suggests
that many patients presented with advanced disease. As the study
contained no comparator arm, it is impossible to say whether
better anti-fungal therapy would have improved outcomes in late
presenters with worse neurological deficits. However, it is likely
that public health interventions to encourage earlier presentation
of patients with symptoms of meningitis will augment optimal anti-
fungal treatments.
CD4 count data were incomplete, however several patients with
extremely low CD4 counts survived to one year (median CD4
count amongst 13 long-term survivors: 13 (IQR 4–41) cells/ml).
This illustrates the potential for full recovery from cryptococcal
meningitis provided an adequate framework is in place to ensure
uninterrupted supply of antifungals and timely commencement of
ART. Without the intensive follow-up afforded by study partic-
ipation, mortality in this group may have been higher.
Prior ART was not associated with improved survival and CD4
counts amongst ART-experienced patients were no higher than
the rest of the cohort. This may represent initiation of ART during
severe immune-suppression (i.e. CD4 count has risen from an
unknown nadir) or ART failure. Irrespective, these data reinforce
Cryptococcal Meningitis Fatality:800mg Fluconazole
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the well documented association between late ART initiation and
higher mortality [27,28] and emphasise the need for early HIV
diagnosis and point of care cryptococcal antigen screening to
detect early cryptococcal disease in high risk patients.
There were some limitations to this work. The sample size was
small. As the study was conducted amidst routine clinical practice
some data were incomplete, precluding multivariate analysis.
Given the constraints of our setting, standardised management of
high CSF pressure was not possible and it was difficult to
characterise all co-morbidities, episodes of IRIS or causes of death
after 4 weeks.
Conclusions
We have described clinical outcomes from cryptococcal
meningitis in patients initiated on 800 mg oral fluconazole
monotherapy. Despite timely ART initiation and uninterrupted
drug supply through near complete follow up, there was
unacceptably high mortality. There is an urgent need to assess
the efficacy of faster acting, combination fungicidal regimens,
particularly in light of recent work on those containing flucytosine
[29,30]. In order to address this, a phase III trial assessing short-
course amphotericin B and oral combination regimens will
commence in 2013 [‘‘Advancing cryptococcal meningitis treat-
ment in Africa’’ (ACTA) ISRCTN: 45035509]. Improvements in
clinical outcomes from cryptococcal meningitis must also involve
public health interventions to encourage early presentation and
roll-out of rapid, point of care diagnostics [31]. Earlier HIV
diagnosis and ART initiation is of equal importance to prevent all
diseases of advanced immunosuppression [32].
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